Targeting CD177: A Novel Therapeutic Strategy for NLRP3-Associated Autoinflammatory Diseases
International Journal of Molecular Sciences · 20.03.2026 · 27 (6) · 2841
DOI: 10.3390/ijms27062841 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.03.2026. Verfasst von Yinghua Zhu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetic Medicine, Dongguan Children's Hospital Affiliated to Guangdong Medical University, Dongguan 523325, China. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Receptors, Cell Surface. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Guangdong Basic and Applied Basic Research Fund (Guangdong-Dongguan Joint Fund), the National Natural Science Foundation of China, Dongguan Eighth People's Hospital doctoral research start-up fund project.
Abstract (Originalsprache)
NLRP3-associated autoinflammatory diseases (NLRP3-AIDs) are rare autoinflammatory disorders caused by uncontrolled inflammasome activation. While IL-1β blockade is first-line therapy, many patients respond inadequately, highlighting a need for alternative strategies. Transcriptomic analysis was performed on immune cells from a patient with an NLRP3 L573W mutation. Functional validation of CD177 as a downstream effector of NLRP3 activation was conducted. A novel NLRP3 L573W knock-in mouse model was established. Correlation between CD177 expression, disease severity, neutrophilia, and tissue damage was assessed. Therapeutic efficacy of siRNA-mediated CD177 silencing was evaluated and compared with IL-1β blockade. CD177, a neutrophil-specific protein, was significantly upregulated in NLRP3-mutant cells and confirmed as a direct downstream effector of NLRP3 activation. The NLRP3 L573W knock-in mouse recapitulated human disease heterogeneity, from mild self-limited inflammation to severe multi-organ pathology. CD177 expression correlated with disease severity, neutrophilia, and tissue damage. siRNA-mediated CD177 silencing attenuated systemic inflammation, reduced neutrophil infiltration and cytokine levels (IL-1β, IL-6, TNFα), and ameliorated multi-organ damage, with effects comparable to or exceeding those of IL-1β blockade. CD177 is a non-canonical amplifier of NLRP3-driven inflammation. Targeting CD177 represents a superior therapeutic strategy for NLRP3-AIDs, including IL-1β-refractory cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Genetic Medicine, Dongguan Children's Hospital Affiliated to Guangdong Medical University, Dongguan 523325, China.
- Key Laboratory for Children's Genetics and Infectious Diseases of Dongguan, Dongguan 523323, China.
- Department of Medical and Molecular Genetics, Dongguan Institute of Pediatrics, Dongguan 523325, China.
- School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Förderung
- the Guangdong Basic and Applied Basic Research Fund (Guangdong-Dongguan Joint Fund)
- the National Natural Science Foundation of China
- Dongguan Eighth People's Hospital doctoral research start-up fund project
- Guangdong Basic and Applied Basic Research Fund
- National Natural Science Foundation of China
- Dongguan Eighth People’s Hospital doctoral research start-up fund project
Zitieren
APA
Zhu, Y., Zhang, F., Li, S., Tian, Z., Jiang, Z., Lv, F., Zeng, X., Zhou, Z., Zhong, B., Peng, Q., & Lu, X. (2026). Targeting CD177: A Novel Therapeutic Strategy for NLRP3-Associated Autoinflammatory Diseases. International Journal of Molecular Sciences, 27(6), 2841. https://doi.org/10.3390/ijms27062841
Vancouver
Zhu Y, Zhang F, Li S, Tian Z, Jiang Z, Lv F, et al. Targeting CD177: A Novel Therapeutic Strategy for NLRP3-Associated Autoinflammatory Diseases. International Journal of Molecular Sciences. 2026;27(6):2841. doi:10.3390/ijms27062841
BibTeX
@article{Zhu2026,
author = {Zhu, Yinghua and Zhang, Fangfang and Li, Siping and Tian, Zhihua and Jiang, Zaixue and Lv, Fen and Zeng, Xiaomei and Zhou, Zhongjun and Zhong, Baimao and Peng, Qi and Lu, Xiaomei},
title = {Targeting CD177: A Novel Therapeutic Strategy for NLRP3-Associated Autoinflammatory Diseases},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {6},
pages = {2841},
doi = {10.3390/ijms27062841}
}
EUVIMED